Sign in
Taking peopleNo phase

Comparison of Transcatheter Edge-to-edge Repair Using Echo Only with Echo Combined with X Ray for Mitral Regurgitation (ECHO-CLIP)

Key facts

Who runs it
Pan Xiangbin
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Recruiting
People taking part
200 people, planned
Started
29 Mar 2024
Planned end
31 Oct 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Echocardiographic guidance
  • Fluoroscopic guidance
Record updated
12 November 2024

Who can take part

Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (17)Hide the full registry criteria

Who can take part

  • *Subjects meet either the first or second inclusion criteria in combination with the third and fourth ones were eligible
  • Symptomatic DMR subjects with MR ≥ 3+ at high surgical risk in terms of STS Predicted Risk of Mortality replacement score ≥ 8 or STS Predicted Risk of Mortality repair score ≥ 6.*
  • FMR subjects with LVESD ≤ 70 mm and MR ≥ 3+, despite administration of GDMT for 30 days.*
  • MV anatomy appropriate for TEER procedure
  • Subjects willing to participate in this study and complete the follow-up on schedule after obtaining informed consent

Who cannot take part

  • Myocardial infarction within 12 weeks prior to randomization
  • Need for concurrent other cardiac procedures
  • Any endovascular intervention or surgery within 30 days prior to randomization
  • Previous MV surgery or current implanted ventricular assist device or current implanted mechanical prosthetic valve
  • Active endocarditis or rheumatic heart disease
  • LVEF < 20%
  • History of DVT or PE; Abbreviations: DMR, degenerative mitral regurgitation; MR, mitral regurgitation; STS, Society of Thoracic Surgeons; FMR, functional mitral regurgitation; LVESD, left ventricular end-systolic diameter; GDMT, guideline-directed medical therapy; TEER, transcatheter edge-to-edge repair; LVEF, left ventricular ejection fraction; MV, mitral valve; DVT, deep venous thrombosis; PE, pulmonary embolism
  • MV orifice area < 4.0 cm2
  • Pulmonary artery systolic pressure > 70 mmHg, as determined by echocardiogram
  • Severe mitral annular calcification
  • Unsuitable MV anatomy potentially precluding clip implantation: leaflet calcification or significant leaflet cleft in the grasping zone
  • Any intracardiac mass, thrombus, or vegetation, as evidenced by echocardiogram

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Mitral regurgitation

This trial is currently available in China.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

Mitral regurgitation (MR) is a common valvular heart disease in the elderly population, frequently associated with poor prognosis if not treated. Transcatheter edge-to-edge repair (TEER) has recently emerged as a popular strategy due to minimal invasiveness. What's more, previous studies, such as EVEREST II and COAPT study, have demonstrated its efficacy in high-risk patients with primary or secondary MR. Conventional TEER procedure, however, is performed under combined guidance of both echocardiography and fluoroscopy, which potentially results in high radiation exposure and limits its application. Since 2021 2021, the investigators have changed the procedural methodology by performing TEER under full echocardiographic guidance on accumulated dozens of MR patients successfully. To confirm the efficacy of a fully echo-guided TEER procedure, the investigators conduct the ECHO-CLIP study to compare its outcomes with the conventional TEER procedure, as well as evaluate the outcomes of this novel methodology in special populations with radiation contraindications. ECHO-CLIP study is a prospective, multicenter, open-label, noninferior, randomized controlled trial of TEER by two different methodological strategies in treating severe primary or secondary MR. It is anticipated to enroll a total of 200 patients as well to complete the enrollment before Dec 31, 2025 and the follow-up before Dec 31, 2026. This work will potentially demonstrate the feasibility and efficacy of the fully echo-guided TEER procedure, thereby revolutionizing the TEER methodology and benefiting more patients.

The 2 groups in the trial

  • Echocardiography-guided groupTreatment being tested

    Patients randomized to the echocardiography-guided group will undergo TEER procedure under fully echo guidance.

    Treatment: Echocardiographic guidance

  • Fluoroscopy-guided groupExisting treatment, for comparison

    Patients randomized to the fluoroscopy-guided group will undergo TEER procedure under combined guidance of X ray and echo.

    Treatment: Fluoroscopic guidance

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
A Randomized Clinical Trial of Transcatheter Edge-to-edge Repair for Mitral Regurgitation Under Fully Echocardiographic Guidance Compared with Under Combined Guidance of Both Echocardiography and Fluoroscopy (ECHO-CLIP Study)
Criteria questions
Built from NCT06684171, who can take part
Publications
Record updated
12 November 2024